These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7770726)

  • 1. Cytotoxic potency of CD22-ricin A depends on intracellular routing rather than on the number of internalized molecules.
    van Horssen PJ; van Oosterhout YV; de Witte T; Preijers FW
    Scand J Immunol; 1995 Jun; 41(6):563-9. PubMed ID: 7770726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells.
    van Horssen PJ; van Oosterhout YV; Evers S; Backus HH; van Oijen MG; Bongaerts R; de Witte T; Preijers FW
    Leukemia; 1999 Feb; 13(2):241-9. PubMed ID: 10025898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
    Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
    Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
    Shen GL; Li JL; Ghetie MA; Ghetie V; May RD; Till M; Brown AN; Relf M; Knowles P; Uhr JW
    Int J Cancer; 1988 Nov; 42(5):792-7. PubMed ID: 3263328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxicity of CD3-ricin A chain immunotoxins in relation to cellular uptake and degradation kinetics.
    van Oosterhout YV; Preijers FW; Wessels HM; de Witte T
    Cancer Res; 1992 Nov; 52(21):5921-5. PubMed ID: 1394218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
    Mansfield E; Amlot P; Pastan I; FitzGerald DJ
    Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
    Herrera L; Farah RA; Pellegrini VA; Aquino DB; Sandler ES; Buchanan GR; Vitetta ES
    Leukemia; 2000 May; 14(5):853-8. PubMed ID: 10803517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
    Shen GL; Li JL; Vitetta ES
    J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains.
    Ghetie V; Swindell E; Uhr JW; Vitetta ES
    J Immunol Methods; 1993 Nov; 166(1):117-22. PubMed ID: 8228282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
    Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
    Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
    Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
    Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins.
    May RD; Vitetta ES; Moldenhauer G; Dörken B
    Cancer Drug Deliv; 1986; 3(4):261-72. PubMed ID: 2436739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model.
    Van Horssen PJ; Preijers FW; Van Oosterhout YV; Eling WM; De Witte T
    Leuk Lymphoma; 2000 Nov; 39(5-6):591-9. PubMed ID: 11342342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins.
    van Oosterhout YV; van den Herik-Oudijk IE; Wessels HM; de Witte T; van de Winkel JG; Preijers FW
    Cancer Res; 1994 Jul; 54(13):3527-32. PubMed ID: 7516821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
    French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
    Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive endocytosis and degradation of CD22 by human B cells.
    Shan D; Press OW
    J Immunol; 1995 May; 154(9):4466-75. PubMed ID: 7722303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
    Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
    Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
    Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD22 antigen: biosynthesis, glycosylation and surface expression of a B lymphocyte protein involved in B cell activation and adhesion.
    Schwartz-Albiez R; Dörken B; Monner DA; Moldenhauer G
    Int Immunol; 1991 Jul; 3(7):623-33. PubMed ID: 1716973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.